CONTEXT: Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach. OBJECTIVE: To critically review the recent data on the management of NMIBC to arrive at a general consensus. EVIDENCE ACQUISITION: A detailed Medline analysis was performed for original articles addressing the treatment of NMIBC with regard to diagnosis, surgery, intravesical chemotherapy, and follow-up. Proceedings from the last 5 yr of major conferences were also searched. EVIDENCE SYNTHESIS: The major findings are presented in an evidence-based fashion. We analyzed large retrospective and prospective studies. CONCLUSIONS: Urothelial cancer of the bladder staged Ta, T1, and carcinoma in situ (CIS), also indicated as NMIBC, poses greatly varying but uniformly demanding challenges to urologic care. On the one hand, the high recurrence rate and low progression rate with Ta low-grade demand risk-adapted treatment and surveillance to provide thorough care while minimizing treatment-related burden. On the other hand, the propensity of Ta high-grade, T1, and CIS to progress demands intense care and timely consideration of radical cystectomy.
CONTEXT: Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach. OBJECTIVE: To critically review the recent data on the management of NMIBC to arrive at a general consensus. EVIDENCE ACQUISITION: A detailed Medline analysis was performed for original articles addressing the treatment of NMIBC with regard to diagnosis, surgery, intravesical chemotherapy, and follow-up. Proceedings from the last 5 yr of major conferences were also searched. EVIDENCE SYNTHESIS: The major findings are presented in an evidence-based fashion. We analyzed large retrospective and prospective studies. CONCLUSIONS:Urothelial cancer of the bladder staged Ta, T1, and carcinoma in situ (CIS), also indicated as NMIBC, poses greatly varying but uniformly demanding challenges to urologic care. On the one hand, the high recurrence rate and low progression rate with Ta low-grade demand risk-adapted treatment and surveillance to provide thorough care while minimizing treatment-related burden. On the other hand, the propensity of Ta high-grade, T1, and CIS to progress demands intense care and timely consideration of radical cystectomy.
Authors: Ashish M Kamat; J Alfred Witjes; Maurizio Brausi; Mark Soloway; Donald Lamm; Raj Persad; Roger Buckley; Andreas Böhle; Marc Colombel; Joan Palou Journal: J Urol Date: 2014-03-25 Impact factor: 7.450
Authors: Ashish M Kamat; Daniel L Willis; Rian J Dickstein; Rooselvelt Anderson; Graciela Nogueras-González; Ruth L Katz; Xifeng Wu; H Barton Grossman; Colin P Dinney Journal: BJU Int Date: 2015-07-03 Impact factor: 5.588
Authors: Mirentxu Santos; Mónica Martínez-Fernández; Marta Dueñas; Ramón García-Escudero; Begoña Alfaya; Felipe Villacampa; Cristina Saiz-Ladera; Clotilde Costa; Marta Oteo; José Duarte; Victor Martínez; Mª José Gómez-Rodriguez; Mª Luisa Martín; Manoli Fernández; Patrick Viatour; Miguel A Morcillo; Julien Sage; Daniel Castellano; Jose L Rodriguez-Peralto; Federico de la Rosa; Jesús M Paramio Journal: Cancer Res Date: 2014-09-24 Impact factor: 12.701
Authors: Abhijith D Mally; Amy L Tin; Justin K Lee; Prassannah Satasivam; Eugene K Cha; S Michele Donat; Harry W Herr; Bernard H Bochner; Daniel D Sjoberg; Guido Dalbagni Journal: Clin Genitourin Cancer Date: 2017-07-14 Impact factor: 2.872